Our Medical Technology Research and Development at a Glance

The Science Behind the Tech


Sustained Acoustic Medicine (sam®) & OZ Inside™

ZetrOZ Systems develops a portfolio of wearable, drug free, non-invasive devices to deliver Long Duration Low Intensity Ultrasound

Thanks to millions of dollars of federal funding, ZetrOZ Systems has developed OZ Inside™, our patented ultra-low impedance ultrasound miniaturization technology, to enable the flexible delivery of sustained acoustic medicine, a new treatment form. It effectively streamlines system architecture and optimizes electro-acoustic signal conduction to achieve peak efficiencies across the entire spectrum of ultrasound outputs.

While the use of traditional therapeutic ultrasound is typically applied in short, high-intensity bursts from large systems, current research indicates that low intensity, long duration ultrasound provides an overall better and sustained solution.

  • Clinically proven mechnobiologic, long duration ultrasound for the treatment of tendon, muscle and joint injuries
  • Beyond pain relief, it accelerates the bodies natural healing process
  • Patient-focused , easy to use and economically sound

OZ Inside™ addresses this new protocol. Not restricted by acoustic power, frequency, or intensity, OZ Inside enables the delivery of sustained acoustic medicine through a wearable device designed for user flexibility.

Peer-reviewed basic science, engineering and clinical publications

Level 1-5 clinical studies on sustained acoustic medicine


Funded by the US Government and Private Foundations to Improve Healthcare

Research & Development

Research & Development at ZetrOZ Systems is focused on developing a portfolio of bioelectronic devices delivering sustained acoustic medicine to treat pain and enhance healing. We concentrate on conditions insufficiently addressed by current treatments and for which large market opportunities exist. The lead product in our pipeline is directed at providing pain relief from back and joint pain.

With funding from the National Institute of Health, National Science Foundation, Department of Defense and NASA, ZetrOZ Systems has shown that daily, sustained acoustic medicine accelerates soft tissue healing, and provides symptomatic relief of knee pain related to osteoarthritis (OA) and back pain related to herniated disks. The success of this research has supported insurance coverage of sam® for arthritis pain of the knee, hip, shoulder, and elbow.  

In our clinical pipeline, we are studying the use of sustained acoustic medicine for additional applications. Research supported by the National Space Biomedical Research Institute, the United States Department of Defense, CIMIT (Center for Integration of Medicine & Innovative Technology), Connecticut Innovations, and the Connecticut Department of Economic and Community Development has validated the efficacy of sam® for the treatment of upper and lower back pain, and to accelerate the healing of soft-tissue injuries.

The company’s research is frequently presented at scientific conferences and meetings in the United States and internationally. In addition, there are more than 45 publications detailing the results of research related to ultrasound therapy.


Intellectual Property

ZetrOZ Systems has a portfolio of 48 patents protecting the therapy innovation of sustained acoustic medicine. The United States and International patents protect the system design, technology, and include registration and trademarks.

International protection is in place through PCT (Patent Cooperation Treaty), with Europe, China, India, and Brazil.

FCOI Policy

ZetrOZ Systems, LLC. Financial Conflict of Interest (FCOI) Policy

We have processes in place to safeguard the integrity of ZetrOZ Systems research and to comply with federal regulations ensuring the design, conduct and reporting of research funded under National Institutes of Health or cooperative agreements will be free from bias resulting from Investigator financial conflicts of interest.

Our FCOI policy has been developed to address and comply with the specific federal agency requirements as defined in the 2011 Revised Financial Conflict of Interest Regulation, Promoting Objectivity in Research (42 CFR part 50 subpart F). The regulation is found at http://www.gpo.gov/fdsys/pkg/FR-2011-08-25/pdf/2011-21633.pdf.

The digital version of ZetrOZ Systems FCOI Policy is found at: https://zetroz.com/wp-content/uploads/2021/05/ZG-8138-00-ZetrOZ-FCOI-Policy.pdf